Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,” Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented, “Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added, “ Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,” Argobio Entrepreneur in Residence Yves Ribeill, PhD said. “The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005337/en/
Contact information
NewCap – Media relations:
Nicolas Merigeau – nmerigeau@newcap.fr – +33 1 44 71 94 98
Arthur Rouillé – arouille@newcap.fr – +33 1 44 71 00 15
Argobio:
Yves Ribeill – yves.ribeill@argobiostudio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Raises $60 million USD in New Funding29.4.2025 15:15:00 EEST | Press release
1NCE, one of the fastest growing providers of IoT software and connectivity, today announced the completion of a $60 million USD funding round. 1NCE offers a software platform for connected products to more than 24,000 customers managing 30 million devices across 170+ countries. Since launching in the marketplace in 2018, the company has become an IoT industry disruptor by integrating connectivity as a component of its software platform. It currently operates the world’s largest IoT network in the cloud. 1NCE’s platform was recognized as the “Best Innovation in the Internet of Things” at the 2024 SaaS Awards. Since 2017, 1NCE has raised the equivalent of $160 million USD from investors from five countries. 1NCE’s list of investors to date now includes Deutsche Telekom, iSquared Capital, Kensington Capital Partners, SoftBank Corp., Vicenda Group, and Founder Alexander P. Sator. The funding round supports 1NCE’s plan to continue its global expansion, which started in 2022 with a focus on
Earnix, the Category Leader in Dynamic AI for the Insurance Industry, Acquires Zelros to Transform Insurers’ Business Performance29.4.2025 15:10:00 EEST | Press release
Earnix, the leading Dynamic AI platform for Insurance, today announced that it has signed a definitive agreement to acquire Zelros, a pioneer in Generative AI for insurers and banks. This innovative collaboration will bring the power of predictive, generative, and agentic AI across the entire risk decisioning, personalization, and claims cycle, thereby enabling pricing and underwriting professionals to deliver compelling offers while improving business performance. By combining Earnix’s advanced Predictive AI platform with Zelros’s GenAI recommendations engine, providers can now present the right offer, at the right price, at the right time. The joint offering provides precise decision-making at scale in regulated environments for pricing and product managers, underwriters, and agents, ultimately resulting in higher conversion rates with better customer engagement and satisfaction. Both companies bring demonstrated impact in supporting leading insurers and banks across the globe, inclu
NetApp Sets New Standard for Cybersecurity at the Storage Layer29.4.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced new data security capabilities that help customers strengthen their cyber resiliency. Security teams can now leverage NetApp, the most secure storage on the planet, to take a proactive approach to data security at the storage layer and strengthen their overall security posture. Advancements in technology drive a cycle of innovation for cyber threats and cybersecurity countermeasures alike. The increasing accessibility of AI has enabled malicious actors to automate cyberattacks, requiring businesses to use machine learning to automate threat detection. And as quantum computing approaches viability, businesses urgently need to protect their data from malicious hackers who may look to steal and store sensitive information today, holding it for the promise of easily accessible quantum-powered decryption in the near future. NetApp is a pioneer of comprehensive, secure-by-design intelligent data infrastructu
AMGTA Gathers at Member Summit to Champion Sustainable Additive Manufacturing29.4.2025 14:00:00 EEST | Press release
The Additive Manufacturer Green Trade Association (AMGTA), a global trade group focused on promoting sustainable and resource efficient manufacturing through 3D-printing and related additive manufacturing (AM) technologies held its 2025 Annual Member Summit April 7th at The Shinola Hotel in Detroit. Over 80 delegates from around the globe attended and contributed to the sharing of practices and technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425092570/en/ Attendees heard from keynote speaker Rich Voorberg, President of Siemens Energy North America, on how additive manufacturing capabilities are transforming spare part inventories, refurbishment and maintenance, and creating bottom-line value through streamlined supply chains. AMGTA Executive Director Sherri Monroe engaged Dr. Dean Bartles, President and CEO of Manufacturing Technology Deployment Group, in a one-on-one discussion of the state of advanced and a
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities29.4.2025 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States. HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom